PCI Biotech file patents for combination of siRNA and the PCI technology

21-Mar-2007

Photocure's daughter company PCI Biotech is developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalisation (PCI). PCI Biotech has, according to an agreement with Rikshospitalet-Radiumhospitalet HF, filed two patent applications covering the combination of siRNA (short interfering RNA) and the PCI technology. PCI Biotech plans to explore this field of the PCI-technology and will sponsor a dedicated research position within this field the next three years.

Kjetil Hestdal, President and CEO of Photocure, says: "Achieving safe and efficient gene delivery in the body has been a major limiting factor in the development of gene therapy. Our goal is to develop an effective treatment of cancer therapy through the combination of siRNA and the PCI technology."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.